Logo Cepheid
Demande de renseignements
Emplacement/Langue

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

{{initials}}
Main Menu
Emplacement/Langue

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

Demande de renseignements
Demande de renseignements

Xpert® vanA

Order Now
Van A computer generated depiction.

On-demand testing to assist with VRE surveillance in around 48 minutes. Résultats positifs disponibles en seulement 45 minutes avec fin prématurée de l’essai (EAT/Early Assay Termination).

Le besoin

an ill woman listens to a physician
  • Vancomycin Resistant Enterococci (VRE) are a growing public health threat and pose a risk to patient safety in healthcare facilities1
  • In healthcare settings, colonized patients and environmental contamination contribute to VRE spread1
  • High-risk patients colonized with VRE have 24 times increased infection risk2
  • Infections caused by VRE are associated with high mortality3
  • VRE has an impact on patient length-of-stay, and in turn, hospitalization costs3
1 Levitus M, et al. Vancomycin-Resistant Enterococci. StatPearls 17 juillet 2023. https://www.ncbi.nlm.nih.gov/books/NBK513233/?report=reader#_NBK513233_pubdet. Consulté 11 décembre 2023.

2 Alevizakos M, et al. Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: (Effet des tests diagnostiques moléculaires rapides sur les résultats cliniques des infections sanguines : un examen systématique et une méta-analyse.) Forum ouvert Infect Dis. 2016 Dec;4(1):ofw246.

3 Eichel V,M, et al. Epidemiology and outcomes of vancomycin-resistant enterococcus infections: (Effet des tests diagnostiques moléculaires rapides sur les résultats cliniques des infections sanguines : un examen systématique et une méta-analyse.) Journal of Hospital Infection 141 (2023) 119e128

La solution

a male and a female researchers scanning cepheid test cartridges
  • The Xpert vanA test is a rapid molecular detection of the vanA gene associated with VRE colonization risk to aid in the recognition, prevention, and control of vancomycin-resistant organisms that colonize patients in healthcare settings
  • Fast, active screening of high-risk patients to support infection control measures in healthcare settings4
4 Babady N,E, et al. Performance Characteristics of the Cepheid Xpert vanA Assay for Rapid Identification of Patients at High Risk for Carriage of Vancomycin-Resistant Enterococci. Journal of Clinical Microbiology, November 2012 Volume 50 Number 11 p. 3659–3663

L’impact

a smiling female doctor attends an elderly woman
Published studies have reported improved infection control workflows following implementation of rapid molecular screening5
  • 93% reduction of turnaround time from 70.5h with chromogenic agar culture to 4.6h
  • High negative predictive value allows for better management of non-colonized patients
  • Associated with a reduction in the number of identified contact patients
Published studies have reported reductions in isolation days following implementation of rapid vanA screening6:
  • 141 saved isolation days and 292 saved transmission risk days
5 Birgand G, et al. Lucet JC. Détection rapide des entérocoques résistants aux glycopeptides : impact sur la prise de décision et les coûts. Antimicrobial Resistant and Infection Control. 2013 Nov 2:30.

6 Holzknecht BJ, Hansen DS, Nielsen L, Kailow A, Jarløv JO. Screening for vancomycin-resistant enterococci with Xpert® vanA/vanB: diagnostic accuracy and impact on infection control decision making. New Microbes New Infect. 2017 Jan 12;16:54-59

* 1€=1,09$, conversion rate December 15th 2023

Établir une connexion vers de meilleurs résultats

Demande de renseignements

Informations

Get More Insights
Powered by Translations.com GlobalLink Web SoftwarePowered by GlobalLink Web